Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

AbCellera Biologics Inc. (ABCL) vs Tango Therapeutics, Inc. (TNGX)

AbCellera Biologics Inc. and Tango Therapeutics, Inc. are both Biotechnology companies. AbCellera Biologics Inc. and Tango Therapeutics, Inc. are of similar size ($4.2B and $4.2B). AbCellera Biologics Inc. grew revenue faster over the last twelve months: 101.3% against 48.3%. Tango Therapeutics, Inc. has the higher net margin (0.00% vs −248.8%) and the lower return on invested capital (−808.4% vs −42.5%). Across the 16 metrics below, Tango Therapeutics, Inc. leads on 9 and AbCellera Biologics Inc. on 7.

Valuation

Metric ABCL TNGX Biotechnology median
P/E n/m n/m 7.88
P/S 58.69 59.87 11.47
P/B 4.33 3.65 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 51.37 43.62 10.73
Earnings yield (4.25%) (3.37%) (28.84%)
Free cash flow yield (3.16%) (3.86%) (23.03%)

Profitability

Metric ABCL TNGX Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin (340.25%) 0.00% 0.00%
Net margin (248.82%) 0.00% 0.00%
Free cash flow margin (180.84%) 0.00% 0.00%
Return on equity (17.30%) (21.34%) (57.72%)
Return on assets (12.15%) (18.86%) (49.22%)
Return on invested capital (42.52%) (808.35%) 0.00%

Growth

Metric ABCL TNGX Biotechnology median
Revenue growth (TTM) 101.29% 48.29% 5.64%
EPS growth (last fiscal year) 10.91% 26.89% —
Revenue growth, 5-year CAGR (20.27%) 52.13% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ABCL TNGX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 12.77 50.82 4.73
Net debt to EBITDA 2.97 3.08 0.96

Dividend

Metric ABCL TNGX Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric ABCL TNGX Biotechnology median
Market cap 4.15b 4.15b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack